Cameron joined Repare Therapeutics in mid-2016 to lead the drug discovery efforts on newly identified synthetic lethal targets. Prior to this, he spent 18 years at Merck Frosst during which time he was responsible for the identification of seven drug candidates. He led both the discovery and early clinical development of the cathepsin K inhibitor odanacatib, a once-weekly treatment for osteoporosis.
In 2010 he was made Site Scientific Operations Lead, responsible for the objectives and staffing of all discovery programs at Merck Frosst. Cameron went on to co-found Kaneq Pharma in 2010 and Kanyr Pharma in 2013 to develop drugs targeting metabolic disease and cancer, respectively.
Cameron holds a B.Sc. from the University of Saskatchewan and a Ph.D. in Chemistry from Harvard University.
EVP, Chief Financial Officer
Steve is a senior finance leader with broad experience managing complex, large-scale finance environments. He was most recently CFO of Clementia Pharmaceuticals (NASDAQ: CMTA), which was sold earlier this year to Ipsen S.A. in a transaction valued at US$1.3 billion.
His experience includes nearly a decade at Aptalis Pharma Inc., where he was responsible for the overall corporate controllership function of a multinational pharmaceutical company with approximately $700 million in annual revenue. At Aptalis, he was responsible for SEC reporting and led the preparation of an SEC S-1 registration statement for a U.S. IPO on NASDAQ prior to the successful sale of the company to Forest Labs. His prior experience also includes Chief Financial Officer of Thinking Capital Financial Corporation, a leading Canadian financial technology firm. He currently also sits on the board of Directors of Profound Medical Corp. (NASDAQ: PROF , TSX: PRN) Mr. Forte received his Bachelor of Commerce in Accountancy from Concordia University and is a Certified Professional Accountant in the Province of Quebec and a Certified Information Systems Auditor with ISACA
EVP & Chief Medical Officer
Maria joined Repare Therapeutics in May 2019 as the Executive Vice President, Chief Medical Officer. She is a hematologist/oncologist with 20 years in pharmaceutical and biotechnology companies and has experience in both early drug development and bringing new drugs to global markets, having developed strategies for all stages of cancer drug development and medical affairs.
Prior to joining Repare, Dr. Koehler was Chief Medical Officer at Bicycle Therapeutics. Prior to Bicycle she was VP, Strategy and Innovation for Pfizer Oncology, spearheading major acquisitions and strategic oncology portfolio decisions. She is also served as Oncology Integrated Development Leader at Pfizer, where she led the clinical development of Pfizer’s first-in-class breast cancer medicine, Ibrance® (palbociclib), first approved in 2015 and with sales of more than $4 billion in 2018.
Dr. Koehler received her MD and PhD from the Silesian Medical School in Poland and has co-authored over 150 publications, book chapters and patents.
Lloyd M. Segal
President & CEO
In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.
In 2013, Lloyd was honored by the Financial Times as Outstanding Corporate Director of the Year. He currently acts as Chairman of LMC Diabetes & Endocrinology, North America’s largest community endocrinology and diabetes practice, as a member of the Board of GBC American Fund, a US growth-focused mutual fund, and was Board Chairman of MedReleaf Inc. (TSX:LEAF), Canada’s leading medical cannabis provider until its sale to Aurora Cannabis (TSX:ACB) for $3.2 billion in July, 2018.
Lloyd holds a BA from Brandeis University and an MBA from Harvard Business School.
EVP, Head of Business & Corporate Development
Kim is Executive Vice President, Head of Business & Corporate Development at Repare. Prior to joining Repare, he was Chief Business Officer and Chief Operating Officer at Resilience Therapeutics and CBO/SVP of Corporate Development & Strategy at Epirus Biopharmaceuticals.
He was previously Executive Director at Pfizer, where he held both global operational and strategy roles. There, he helped lead the design and execution of the R&D operational turnaround and led strategic efforts to enter and expand into new markets, as Head, External Strategy & Innovation. In this role, he initiated and led the strategy development and operational launch of Pfizer’s integrated, pan-enterprise Immuno-Oncology platform. Prior to Pfizer, he was Vice President in Global Investment Research at Goldman Sachs, covering the global Specialty and Large Cap Pharmaceutical sectors as an analyst.
Dr. Seth holds an AB cum laude in Economics from Harvard College and a Ph.D. in Neurobiology from Harvard University.
VP, Translational Science
Theresa joined Repare Therapeutics in January 2018 as VP of Translational Science.
Prior to this, she spent 13 years at Merck. She led a team of oncology translational scientists to identify patient stratification biomarkers for early stage compounds and oversaw the development of fit-for-purpose CLIA assays for use in cancer clinical trials.
In 2014 she joined Personal Genome Diagnostics, where she developed cutting-edge liquid biopsy tests for cancer using Next-Generation sequencing technologies.
Theresa received her B.Sc. from Peking University and Bridgewater College and her PhD in Computational Biology from University of Virginia. She completed a Postdoctoral Fellowship in bioinformatics at Cold Spring Harbor Laboratories.
EVP, Chief Scientific Officer
Michael is the Executive Vice President, Chief Scientifc Officer at Repare Therapeutics. Prior to joining Repare, he led the oncology bioscience organization at AstraZeneca R&D Boston. In this role he served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient centric drug discovery programs.
He helped to transform the AstraZeneca pipeline through strategic builds in the immuno-oncology, tumor drivers and resistance and DNA damage response areas. His group delivered multiple novel therapies in the clinic including inhibitors of protein-protein interactions, enzymatic function, bromodomain interactions and nucleic acid based therapeutics in collaboration with Ionis Pharmaceuticals.
Dr. Michael Zinda holds a B.Sc. In Biology from the Minnesota State University Moorhead and a Ph.D. In Molecular Biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company.